1052 Impact of CPAP Adherence on Hospitalized Patients Diagnosed with OSA on Healthcare Utilization in Rural Settings

Priyanka Srinivasan,Edward Rojas,Kassandra Olgers,Scott Knollinger,Calvin Seol,Robert Stansbury,Sunil Sharma

DOI: https://doi.org/10.1093/sleep/zsae067.01052

IF: 6.313

2024-04-20

SLEEP

Abstract:Abstract Introduction Obstructive Sleep Apnea (OSA) is an increasingly prevalent condition with significant implications for cardiopulmonary health. Data suggests that early detection of OSA in hospitalized patients may improve outcomes. However, the effects of CPAP therapy have not been studied for hospitalized patients in a rural population. The primary purpose of this study is to examine the 1-year readmission, ED visit rate, and associated healthcare costs in hospitalized patients screened as high-risk for OSA, diagnosed, and started on CPAP therapy. Methods Through a retrospective review of 2042 patients from 08/2019 to 06/2023 in a registry of a hospital-based sleep medicine program, 786 patients were determined as high risk based on their results from apnea link. From there, 341 patients were selected based on their completion of an outpatient polysomnography (PSG), of which 293 were assessed for adherence of CPAP therapy. Composite end point of combined number of hospitalization and emergency department (ED) visits for 1-year were recorded, further separating the outcomes that were cardiopulmonary in nature due to the CPAP’s focus on those organs. Moreover, cost analysis was performed. Results Of the 293 assessed for adherence of CPAP therapy, 108 patients were adherent, while 185 were non-adherent. The mean age of patients evaluated was 58 years (12.82) and 57% were males. The average BMI of these patients was 39.7 (10.7). The mean AHI was 25.49 (26). Analyses showed that 1-year composite end point of hospital readmissions and ED visits were significantly higher in non-adherent patients compared to adherent patients. The hazard ratio was determined to be 1.24 with 95%CI 1-1.54(p=0.03). In the multivariate Cox model, adjusting for age and gender, the adjusted HR was 1.27 with 95%CI: 1.02 – 1.58 (p = 0.033). The one-year total cost of healthcare was significantly higher among non-adherent patients (p< 0.001). Conclusion Early detection of OSA in hospitalized patients in Appalachia and successful treatment may significantly lower healthcare utilization. These may have practical impact on quality of life and cost of healthcare delivery in rural hospitals. Support (if any)

neurosciences,clinical neurology

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to support the safe use of low - sodium oxybate (LXB; Xywav®) and high - sodium oxybate (SXB; Xyrem®) by investigating the degree of understanding of patients and prescribing physicians regarding the relevant risks, safe handling, and storage of the treatment with these two drugs. Specifically, the study aims to evaluate whether the important information conveyed through the Risk Evaluation and Mitigation Strategy (REMS) program of the US Food and Drug Administration (FDA) is fully understood and followed by patients and physicians. This includes awareness of the risks of drug abuse, dosage guidance, and safe handling and storage.

The research methods include conducting surveys via the Internet, telephone, and paper questionnaires, with the survey subjects including patients receiving treatment with these two drugs and the prescribing physicians. The survey content covers the understanding of the key REMS risk information, such as the risks associated with LXB and SXB, the risks of abuse, dosage, and safe handling.

The research results show that most patients and physicians correctly identified the risks of taking LXB and SXB at the recommended dosage, the risks of abuse, and the risks of overdose. Meanwhile, for the regimen requiring two doses at night, the vast majority of patients and physicians understand that the first dose should be taken before going to bed, the second dose should be taken 2.5 to 4 hours after the first dose, and the patient should stay in bed during these two doses. In addition, most respondents also correctly answered questions regarding the correct storage methods of the drugs, reporting loss or theft, and the legality of giving or selling LXB and SXB.

The conclusion points out that most of the patients and physicians participating in the survey demonstrated an understanding of the risks, dosage instructions, and safe handling of LXB and SXB conveyed through REMS, which helps to support the safe and effective use of these drugs.